Evidence map›Paper›PMID 37875669›Full record

ArticleBreast cancer research and treatment2024

Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer.

Devon K Check, Bradford E Jackson, Katherine E Reeder-Hayes, Michaela A Dinan, Eleanor Faherty, Jackie Kwong, Sandhya Mehta, Lisa Spees, Stephanie B Wheeler, Lauren E Wilson and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Devon K CheckDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, Suite 210, Durham, NC, 27701, USA. Devon.check@duke.edu.ORCID http://orcid.org/0000-0002-0673-879X
Bradford E JacksonUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Katherine E Reeder-HayesUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michaela A DinanYale Cancer Center, New Haven, CT, USA.
Eleanor FahertyAstraZeneca, Gaithersburg, MD, USA.
Jackie KwongDaiichi Sankyo, Basking Ridge, NH, USA.
Sandhya MehtaDaiichi Sankyo, Basking Ridge, NH, USA.
Lisa SpeesUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Stephanie B WheelerUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lauren E WilsonDepartment of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, Suite 210, Durham, NC, 27701, USA.
Clara LamAstraZeneca, Gaithersburg, MD, USA.
University of North Carolina at Chapel Hill · USAstraZeneca (United States) · USDaiichi Sankyo (United States) · USDuke University · USYale Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTreatment for HER2-low [defined as ImmunoHistoChemistry (IHC) 1 + or 2 + and negative/normal in Situ Hybridization (ISH)] breast cancer patients is rapidly evolving, yet we lack critical information about the HER2-low population.

methodsWe conducted a retrospective cohort study of women aged 18 years or older diagnosed with breast cancer between 2010 and 2016 in North Carolina. Analyses were conducted for the overall cohort and a stage IV sub-cohort. We examined demographic and clinical characteristics, and characterized prevalence of HER2-low disease and healthcare utilization. We estimated adjusted rate ratios for the association between HER2 classifications and utilization outcomes, and hazard ratios for 3-year all cause mortality (stage IV only).

resultsThe overall and stage IV cohorts included 12,965 and 635 patients, respectively. HER2-low patients represented more than half of both cohorts (59% overall, 53% stage IV). HER2-low patients were more likely than IHC 0 patients to have hormone receptor (HR)-positive disease. In the stage IV cohort, HER2-low patients were more likely to be Black (26% vs. 16% IHC 0, p = 0.0159). In both cohorts, rates of hospitalizations were slightly higher among HER2-low patients. There were no survival differences between HER2-low and IHC 0 among stage IV patients.

conclusionNew treatment options for HER2-low breast cancer may have potential for significant impact at the population level particularly for patients with stage IV disease. In light of racial differences between HER2-low and IHC 0 patients observed in our cohort, research- and practice-based efforts to ensure equitable adoption of new treatment guidelines for patients with HER2-low metastatic breast cancer will be essential.

Indexed as

Breast NeoplasmsDelivery of Health CareErb-b2 Receptor Tyrosine KinasesFemaleHumansPatient Acceptance of Health CareRetrospective StudiesErb-b2 Receptor Tyrosine KinasesAdministrative claimsEpidemiologyHealthcare resource utilizationHER2-lowMetastatic breast cancer

Identifiers

PMID37875669
OpenAlexW4387901859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.